Difference between revisions of "Raltitrexed (Tomudex)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
|||
| Line 18: | Line 18: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] | ||
[[Category:Antifolates]] | [[Category:Antifolates]] | ||
Revision as of 16:55, 25 July 2017
General information
Class/mechanism: Antimetabolite, inhibitor of thymidylate synthase. Not approved by the FDA. Raltitrexed is a quinazoline folate analogue which inhibits thymidylate synthase (TS). TSis an enzyme involved in the synthesis of thymidine triphosphate (TTP), a nucleotide required
exclusively for DNA synthesis. Inhibiting TS causes DNA damage and cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
No information available.
Also known as
Raltitrexed disodium, TDX, ZD 1694